Trelleborg Medical Solutions expands testing capabilities for pharmaceutical customers

Trelleborg Medical Solutions announces the opening of its new 490 square feet/46 square meters laboratory space for analytical testing to support the development of sustained-release and drug-elution technologies. 

Trelleborg Medical Solutions, a world leader in innovative, reliable engineered polymer solutions for demanding medical, biotech and pharmaceutical applications, created the dedicated laboratory space to deliver part of its strategic goal to be a total solution provider for pharmaceutical original equipment manufacturers.

Don Bonitati, Americas Segment Director, Trelleborg Medical Solutions, says: “We are equipped to support customers that need to transfer an existing test method or develop a new one. Not every pharmaceutical company has the capacity or experience to perform its own product release testing. We recognize that each product is unique, so we’ve established methods that fit a product's specific characteristics, ensuring accurate and reliable results while maintaining cost-effectiveness. 

Scroll to continue with content

“Be it early-stage development, clinical production, manufacturable scalability or market product support, our analytical team can help. We can assist with anything from study design and method development to the execution of tests that provide meaningful data to advance implantable drug delivery systems and combination devices.”

At the laboratory in Tustin, California, experts conduct material characterization and oversee products to development. To ensure commercial performance, they use Current Good Manufacturing Practice (cGMP) requirements. Finally, scientists analyze active pharmaceutical ingredients (APIs) which are the substances responsible for the therapeutic action of the drug, excipient polymers and other materials.